BIOMAT Database Logo BIOMAT Database Logo

[Cardiovascular-active agents. Problems of dosage and adverse effects]. 1971

W Baedeker

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D010138 Pacemaker, Artificial A device designed to stimulate, by electric impulses, contraction of the heart muscles. It may be temporary (external) or permanent (internal or internal-external). Cardiac Pacemaker, Artificial,Artificial Cardiac Pacemaker,Artificial Cardiac Pacemakers,Artificial Pacemaker,Artificial Pacemakers,Cardiac Pacemakers, Artificial,Pacemaker, Artificial Cardiac,Pacemakers, Artificial,Pacemakers, Artificial Cardiac
D001919 Bradycardia Cardiac arrhythmias that are characterized by excessively slow HEART RATE, usually below 50 beats per minute in human adults. They can be classified broadly into SINOATRIAL NODE dysfunction and ATRIOVENTRICULAR BLOCK. Bradyarrhythmia,Bradyarrhythmias,Bradycardias
D002301 Cardiac Glycosides Cyclopentanophenanthrenes with a 5- or 6-membered lactone ring attached at the 17-position and SUGARS attached at the 3-position. Plants they come from have long been used in congestive heart failure. They increase the force of cardiac contraction without significantly affecting other parameters, but are very toxic at larger doses. Their mechanism of action usually involves inhibition of the NA(+)-K(+)-EXCHANGING ATPASE and they are often used in cell biological studies for that purpose. Cardiac Glycoside,Cardiotonic Steroid,Cardiotonic Steroids,Glycoside, Cardiac,Glycosides, Cardiac,Steroid, Cardiotonic,Steroids, Cardiotonic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000319 Adrenergic beta-Antagonists Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety. Adrenergic beta-Antagonist,Adrenergic beta-Receptor Blockader,Adrenergic beta-Receptor Blockaders,beta-Adrenergic Antagonist,beta-Adrenergic Blocker,beta-Adrenergic Blocking Agent,beta-Adrenergic Blocking Agents,beta-Adrenergic Receptor Blockader,beta-Adrenergic Receptor Blockaders,beta-Adrenoceptor Antagonist,beta-Blockers, Adrenergic,beta-Adrenergic Antagonists,beta-Adrenergic Blockers,beta-Adrenoceptor Antagonists,Adrenergic beta Antagonist,Adrenergic beta Antagonists,Adrenergic beta Receptor Blockader,Adrenergic beta Receptor Blockaders,Adrenergic beta-Blockers,Agent, beta-Adrenergic Blocking,Agents, beta-Adrenergic Blocking,Antagonist, beta-Adrenergic,Antagonist, beta-Adrenoceptor,Antagonists, beta-Adrenergic,Antagonists, beta-Adrenoceptor,Blockader, Adrenergic beta-Receptor,Blockader, beta-Adrenergic Receptor,Blockaders, Adrenergic beta-Receptor,Blockaders, beta-Adrenergic Receptor,Blocker, beta-Adrenergic,Blockers, beta-Adrenergic,Blocking Agent, beta-Adrenergic,Blocking Agents, beta-Adrenergic,Receptor Blockader, beta-Adrenergic,Receptor Blockaders, beta-Adrenergic,beta Adrenergic Antagonist,beta Adrenergic Antagonists,beta Adrenergic Blocker,beta Adrenergic Blockers,beta Adrenergic Blocking Agent,beta Adrenergic Blocking Agents,beta Adrenergic Receptor Blockader,beta Adrenergic Receptor Blockaders,beta Adrenoceptor Antagonist,beta Adrenoceptor Antagonists,beta Blockers, Adrenergic,beta-Antagonist, Adrenergic,beta-Antagonists, Adrenergic,beta-Receptor Blockader, Adrenergic,beta-Receptor Blockaders, Adrenergic
D000787 Angina Pectoris The symptom of paroxysmal pain consequent to MYOCARDIAL ISCHEMIA usually of distinctive character, location and radiation. It is thought to be provoked by a transient stressful situation during which the oxygen requirements of the MYOCARDIUM exceed that supplied by the CORONARY CIRCULATION. Angor Pectoris,Stenocardia,Stenocardias
D001145 Arrhythmias, Cardiac Any disturbances of the normal rhythmic beating of the heart or MYOCARDIAL CONTRACTION. Cardiac arrhythmias can be classified by the abnormalities in HEART RATE, disorders of electrical impulse generation, or impulse conduction. Arrhythmia,Arrythmia,Cardiac Arrhythmia,Cardiac Arrhythmias,Cardiac Dysrhythmia,Arrhythmia, Cardiac,Dysrhythmia, Cardiac
D013565 Sympatholytics Drugs that inhibit the actions of the sympathetic nervous system by any mechanism. The most common of these are the ADRENERGIC ANTAGONISTS and drugs that deplete norepinephrine or reduce the release of transmitters from adrenergic postganglionic terminals (see ADRENERGIC AGENTS). Drugs that act in the central nervous system to reduce sympathetic activity (e.g., centrally acting alpha-2 adrenergic agonists, see ADRENERGIC ALPHA-AGONISTS) are included here. Sympathetic-Blocking Agents,Sympatholytic,Sympatholytic Agent,Sympatholytic Drug,Sympatholytic Agents,Sympatholytic Drugs,Sympatholytic Effect,Sympatholytic Effects,Agent, Sympatholytic,Agents, Sympathetic-Blocking,Agents, Sympatholytic,Drug, Sympatholytic,Drugs, Sympatholytic,Effect, Sympatholytic,Effects, Sympatholytic,Sympathetic Blocking Agents

Related Publications

W Baedeker
[Dosage and adverse effects of psychopharmacological agents].
December 1971, Internationale Zeitschrift fur klinische Pharmakologie, Therapie, und Toxikologie. International journal of clinical pharmacology, therapy, and toxicology,
W Baedeker
[Adverse effects of cardiovascular agents].
October 2007, Nihon rinsho. Japanese journal of clinical medicine,
W Baedeker
[Dosage and adverse effects of commonly used antirheumatic agents].
December 1971, Internationale Zeitschrift fur klinische Pharmakologie, Therapie, und Toxikologie. International journal of clinical pharmacology, therapy, and toxicology,
W Baedeker
[Cardiovascular adverse effects of cytostatic agents].
January 2003, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke,
W Baedeker
[Dosage and adverse effects in the use of antihypertensive and diuretic agents].
December 1971, Internationale Zeitschrift fur klinische Pharmakologie, Therapie, und Toxikologie. International journal of clinical pharmacology, therapy, and toxicology,
W Baedeker
[Metabolic and cardiovascular adverse effects of modern antipsychotic agents].
January 2004, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke,
W Baedeker
[Antibiotics, anti-inflammatory agents, disinfectants and antineoplastic agents--adverse effects and problems].
January 1980, Nihon Shika Ishikai zasshi,
W Baedeker
[Dosage and adverse effect problems in pregnancy].
December 1971, Internationale Zeitschrift fur klinische Pharmakologie, Therapie, und Toxikologie. International journal of clinical pharmacology, therapy, and toxicology,
W Baedeker
[Adverse effects of cardiovascular agents in Japan--update 2012].
August 2012, Nihon rinsho. Japanese journal of clinical medicine,
W Baedeker
Endocrine active agents: implications of adverse and non-adverse changes.
January 2002, Toxicologic pathology,
Copied contents to your clipboard!